A. Vorobyeva

S. Hober, V. Tolmachev, A. Orlova, 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts

V. Tolmachev, A. Orlova, A. Vorobyeva, 2021, The Journal of Nuclear Medicine.

Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake

P. Jonasson, J. Feldwisch, V. Tolmachev, 2021, International journal of molecular sciences.

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors

V. Tolmachev, A. Orlova, Mohamed Altai, 2018, Contrast media & molecular imaging.

Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein

S. Hober, Sara S Rinne, A. Vorobyeva, 2020, Molecules.

Abstracts of the 33rd International Austrian Winter Symposium

M. Knopp, J. Karp, M. Schwaiger, 2018, EJNMMI Research.

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules

S. Ståhl, J. Löfblom, A. Orlova, 2022, Biomedicines.

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177Lu‐DOTAGA‐PEG2‐RM26

V. Tolmachev, A. Orlova, Mohamed Altai, 2019, International journal of cancer.

Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells

A. Schulga, V. Tolmachev, S. Deyev, 2022, Oncology reports.

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model

A. Schulga, V. Tolmachev, A. Orlova, 2021, Cancers.

Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.

A. Schulga, J. Löfblom, V. Tolmachev, 2019, Molecular pharmaceutics.

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model

A. Schulga, V. Tolmachev, A. Orlova, 2023, International journal of molecular sciences.

Development of a Bioluminescent Nitroreductase Probe for Preclinical Imaging

K. Francis, M. Tangney, J. Gelovani, 2015, PloS one.

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis

C. Ekblad, V. Tolmachev, F. Frejd, 2022, Pharmaceutics.

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution

V. Tolmachev, A. Orlova, T. Gräslund, 2021, Pharmaceutics.

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model

V. Tolmachev, A. Orlova, T. Gräslund, 2020, Cancers.

HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers

S. Ståhl, J. Löfblom, V. Tolmachev, 2021, Cancers.

Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m

S. Hober, V. Tolmachev, A. Orlova, 2017, Scientific Reports.

Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Fredrik Y Frejd, V. Tolmachev, F. Frejd, 2023, Cancers.

Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy

S. Hober, A. Schulga, V. Tolmachev, 2022, International journal of molecular sciences.

Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer

A. Schulga, V. Tolmachev, S. Deyev, 2022, International journal of molecular sciences.

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy

A. Karlström, V. Tolmachev, A. Orlova, 2018, Scientific Reports.

Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

A. Schulga, V. Tolmachev, A. Orlova, 2021, The Journal of Nuclear Medicine.

Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3

A. Schulga, J. Löfblom, V. Tolmachev, 2019, Scientific Reports.

Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2

J. Löfblom, V. Tolmachev, A. Orlova, 2019, International journal of oncology.

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain

P. Jonasson, V. Tolmachev, F. Frejd, 2021, Pharmaceutics.

Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle.

S. Hober, V. Tolmachev, A. Orlova, 2020, Biomaterials.

Phase I Study of 99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer

S. Hober, V. Tolmachev, A. Orlova, 2020, The Journal of Nuclear Medicine.

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules

S. Ståhl, J. Löfblom, V. Tolmachev, 2020, International journal of molecular sciences.

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs

S. Ståhl, J. Löfblom, V. Tolmachev, 2018, Cells.

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2

V. Tolmachev, A. Orlova, T. Gräslund, 2022, Pharmaceutics.

Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with 99mTc and 125I

A. Schulga, V. Tolmachev, A. Orlova, 2022, Oncology letters.

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers

S. Ståhl, J. Löfblom, V. Tolmachev, 2019, International journal of molecular sciences.

Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging

A. Schulga, V. Tolmachev, A. Orlova, 2019, International journal of molecular sciences.

Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.

V. Tolmachev, A. Orlova, T. Gräslund, 2023, Journal of controlled release : official journal of the Controlled Release Society.

Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein

S. Hober, V. Tolmachev, A. Orlova, 2021, Pharmaceutics.

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

V. Tolmachev, A. Orlova, Mohamed Altai, 2021, Pharmaceutics.

Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity.

S. Ståhl, J. Löfblom, V. Tolmachev, 2023, Journal of Controlled Release.

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1

A. Schulga, V. Tolmachev, A. Orlova, 2020, International journal of molecular sciences.

Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use

V. Tolmachev, A. Vorobyeva, O. Bragina, 2021, Bulletin of Siberian Medicine.

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake

S. Ståhl, J. Löfblom, V. Tolmachev, 2019, Scientific Reports.

Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6.

S. Hober, V. Tolmachev, A. Orlova, 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

In vitro and in vivo Evaluation of the Radiochemical Compound Based on 99mTechnetium Labelled DARPin 9_29 for Molecular Visualization of Malignancies Overexpressing Her2/neu

V. Tolmachev, S. Deyev, A. Vorobyeva, 2020 .

Half-life extension via ADB-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.

A. Orlova, T. Gräslund, A. Vorobyeva, 2024, Journal of controlled release : official journal of the Controlled Release Society.

On the prevention of kidney uptake of radiolabeled DARPins

A. Schulga, Mohamed Altai, S. Deyev, 2020, EJNMMI Research.